Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: An open-label, randomised, crossover trial

BMC Clinical Pharmacology

Volumn 12, Issue , 2012, Pages

  Kothare, Prajakti A ^a   Seger, Mary E ^a   Northrup, Justin ^a   Mace, Kenneth ^a   Mitchell, Malcolm I ^a   Linnebjerg, Helle ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Exenatide twice daily; Oral contraceptive; Pharmacokinetics

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; EXENDIN 4; ANTIDIABETIC AGENT; ETHINYLESTRADIOL; LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT; PEPTIDE; VENOM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE RASH; MAXIMUM PLASMA CONCENTRATION; MEAL; NAUSEA AND VOMITING; NORMAL HUMAN; OPEN STUDY; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG INTERACTION;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LEVONORGESTREL; PEPTIDES; VENOMS; YOUNG ADULT;

EID: 84858318559     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-12-8     Document Type: Article

References (24)

1. Reddy S, Park S, Fineman M, Jay L, Carter M, Reynolds L, Sanburn N, Kothare PA. Clinical pharmacokinetics of exenatide in patients with type 2 diabetes [abstract]. AAPS J 2005, 7:M1285.
2. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metabol 2006, 7:367-374.
3. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089. 10.1210/jc.2002-021545, 12843147.
4. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
5. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M, Horowitz M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008, 151:123-129. 10.1016/j.regpep.2008.07.003, 18675854.
6. Verdich C, Flint A, Gutzwiller JP, Näslund E, Beglinger C, Hellström PM, Long SJ, Morgan LM, Holst JJ, Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001, 86:4382-4389. 10.1210/jc.86.9.4382, 11549680.
7. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001, 281:E155-E161.
8. Kothare PA, Soon DK, Linnebjerg H, Park S, Chan C, Yeo A, Lim M, Mace KF, Wise SD. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol 2005, 45:1032-1037. 10.1177/0091270005278806, 16100297.
9. Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 2006, 46:1179-1187. 10.1177/0091270006291622, 16988207.
10. Kothare PA, Linnebjerg H, Skrivanek Z, Reddy S, Mace K, Pena A, Han J, Fineman M, Mitchell M. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther 2007, 45:114-120.
11. Linnebjerg H, Kothare P, Park S, Mace K, Mitchell M. The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. Int J Clin Pharmacol Ther 2009, 47:651-658.
12. Blase E, Taylor K, Gao HY, Wintle M, Fineman M. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 2005, 45:570-577. 10.1177/0091270004274432, 15831781.
13. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, Rodrigues AD. Pharmacokinetic drug interactions involving 17[alpha]-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007, 46:133-157. 10.2165/00003088-200746020-00003, 17253885.
14. Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception 2008, 78:4-9. 10.1016/j.contraception.2008.02.020, 18555811.
15. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003, 74:525-535. 10.1016/j.clpt.2003.08.009, 14663455.
16. Boyd RA, Zegarac EA, Eldon MA. The effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy. J Clin Pharmacol 2003, 43:52-58. 10.1177/0091270002239706, 12520628.
17. Byetta (package insert). 2008, San Diego, CA: Amylin Pharmaceuticals, Inc., http://documents.byetta.com/Byetta_PI.pdf
18. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exenatide-113 Clinical Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635. 10.2337/diacare.27.11.2628, 15504997.
19. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100. 10.2337/diacare.28.5.1092, 15855572.
20. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091. 10.2337/diacare.28.5.1083, 15855571.
21. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
22. World Medical Association Declaration of Helsinki ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3045. World Medical Association Declaration of Helsinki.
23. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001. The European Parliament and the Council of the European Union., http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500011204&murl=menus/document_library/document_library.jsp&mid=WC0b01ac058009a3dc
24. Li W, Li YH, Li AC, Zhou S, Naidong W. Simultaneous determination of norethindrone and ethinyl estradiol in human plasma by high performance liquid chromatography with tandem mass spectrometry-experiences on developing a highly selective method using derivatization reagent for enhancing sensitivity. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 825:223-232. 10.1016/j.jchromb.2005.01.012, 16213451.